Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00526812 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT00526812 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 54 participants.
The verdict
NCT00526812, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.
Interventions
- DRUG RTA 744
- DRUG RTA 744 injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2005-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00526812
The ClinicalTrials.gov registry entry for NCT00526812 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which RTA 744 is the first listed.
NCT00526812 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00526812 about?
NCT00526812 is a clinical study titled "A Safety Study of RTA 744 in Patients With Recurrent High-Grade Gliomas". This study assesses the tolerability, safety, efficacy and pharmacokinetics of RTA 744 in recurrent high-grade gliomas.
What is the current status of trial NCT00526812?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2005-11-30.
What interventions are being tested in trial NCT00526812?
The interventions under investigation include: RTA 744 (DRUG), RTA 744 injection (DRUG).
Who is sponsoring clinical trial NCT00526812?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.